binding affinity News and Research

RSS

Automated computational protocol identifies potential SARS-CoV-2 MPro inhibitor

As scientists race to discover new and effective antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many novel approaches are being utilized. Now, a new study published on the preprint bioRxiv in September 2020 reports on the discovery of a potentially beneficial enzyme blocker that could inhibit SARS-CoV-2 viral replication.

24 Sep 2020

Bat and pangolin coronavirus structure sheds light on SARS-CoV-2 evolution

Researchers at Tsinghua University, Beijing, have conducted a study providing possible new insights into the evolution and cross-species transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

23 Sep 2020

Molecular dynamic simulations reveal detailed spike-ACE2 interactions

The current COVID-19 pandemic has spread throughout the world. Caused by a single-stranded RNA betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to but much more infectious than the earlier highly pathogenic betacoronaviruses SARS and MERS-CoV, has impacted social, economic, and physical health to an unimaginable extent.

23 Sep 2020

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020

Innovative approach for identifying new molecules to help track progression of Parkinson's

For many of the 200,000 patients diagnosed with Parkinson's disease in the United States every year, the diagnosis often occurs only after the appearance of severe symptoms such as tremors or speech difficulties.

21 Sep 2020

New method isolates antibody-like proteins that capture and neutralize SARS-CoV-2

Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus - 4 of which also exhibited neutralizing activity - within 4 days, according to a new study.

19 Sep 2020

Genetic variants of human ACE2 are differentially recognized by SARS-CoV-2

Scientists at the University of Wisconsin reveals that the genetic variants of human angiotensin 2 (ACE2) receptors can have altered recognition by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. The study is currently available on the bioRxiv* preprint server.

18 Sep 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus - a potentially critical feature of an effective vaccine.

25 Aug 2020

Loss of supporting cells in olfactory epithelium causes loss of smell in COVID-19

In the current pandemic of COVID-19, many patients have reported symptoms of loss of smell and taste. The cellular basis of this phenomenon has not been satisfactorily explained so far. However, a new study published in the Briefings in Bioinformatics in August 2020 shows how this symptom is related to viral pathogenesis.

23 Aug 2020

SARS-CoV-2 poses significant threat to many marine mammal species

A new study conducted by researchers at Dalhousie University in Halifax, Canada, has found that many species of marine mammal are highly vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

De novo protein decoys that block SARS-CoV-2

Now, a new study published on the preprint server bioRxiv in August 2020 shows that computational design technology can be efficiently harnessed towards this end, producing new molecules to inhibit viral entry and replication.

5 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

A new measles-based COVID-19 vaccine

Now, a new study by researchers from Germany's Paul Ehrlich Institute and published on the preprint server bioRxiv in July 2020 describes a potential vaccine based on the measles vaccine, which elicits both an antibody response and cellular immunity against the virus. This also protects against the measles virus. This could be a significant weapon in the fight against these two threats.

14 Jul 2020

Scientists discover common molecular feature found in SARS-CoV-2 neutralizing antibodies

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

13 Jul 2020

No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

In contrast to previous hypotheses, researchers from the University College London and Great Ormond Street Hospital for Children NHS Foundation Trust found no evidence of unique viral sequences from patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Their study is published on the medRxiv* preprint server.

12 Jul 2020

Tracing adaptation to ACE2 use in sarbecoviruses

A detailed study published on the preprint server bioRxiv in July 2020 argues that recombination accounts for the appearance of the ability of both SARS-CoV and SARS-CoV-2 to use the human angiotensin-converting enzyme (hACE) 2 as the binding receptor mediating viral infection of human cells.

8 Jul 2020